ELCC, GENEVA, 11 - 14 APRIL 2018

Afatinib in patients with EGFR mutation-positive NSCLC harbouring
uncommon mutations: overview of clinical data

Angela Märten, Nobuyuki Yamamoto, Chong-Jen Yu, Sai-Hong I Ou, Caicun Zhou, Wenbo Tang, Yi-Long Wu

ELCC 2018 Afatinib uncommon mutations_poster

Related Materials

Learn more about the science behind this poster in the videos, papers and other materials below.

Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6

Yang et al. Lancet Oncol. 2015 Jul;16(7):830–838

First-line Afatinib for Non-Small Cell Lung Cancer in Real-world Practice

Kim et al. WCLC 2017. Poster P3.01-023

A Phase IIIb open-label, single-arm study of afatinib in EGFR TKI-naïve patients with EGFRm+ NSCLC: An interim analysis

Wu et al. WCLC 2017. Poster P3.01-036

Activity of afatinib in uncommon epidermal growth factor receptor (EGFR) mutations: Findings from three trials of afatinib in EGFR mutation-positive lung cancer

Yang et al. WCLC 2013. Oral



In the European Union, afatinib is approved for use in TKI-naive adults with locally advanced or metastatic NSCLC with activating EGFR mutations and in patients with NSCLC of squamous histology on or after chemotherapy. It is not yet approved in other indications.


In Switzerland, Afatinib is approved as monotherapy for patients with non-small cell lung cancer (NSCLC, stage IIIb/IV) with activating mutations of EGFR (exon 19 deletions or exon 21 L858R substitutions), not previously treated with EGFR TKIs. It is also indicated for the treatment of patients with locally advanced or metastatic squamous cell cancer of the lung whose carcinoma progressed during or after platinum-based chemotherapy and for whom immunotherapy is not suitable.